| Patents for G01N 33 - Investigating or analysing materials by specific methods not covered by groups (393,632) |
|---|
| 01/21/2010 | WO2010008524A1 Capillary driven lateral flow devices |
| 01/21/2010 | WO2010008519A2 In vitro diagnostic markers comprising carbon nanoparticles and kits |
| 01/21/2010 | WO2010008450A2 Chemical sample collection and detection using atmospheric pressure ionization |
| 01/21/2010 | WO2010008315A1 Method for carrying out a qualitative preliminary instant diagnosis of oncological diseases |
| 01/21/2010 | WO2010008159A2 Mass- and property-tuned variable mass labeling reagents and analytical methods for simultaneous peptide sequencing and multiplexed protein quantification using thereof |
| 01/21/2010 | WO2010008137A2 Device for measuring proteins using biosensor |
| 01/21/2010 | WO2010008084A1 Novel use application of sugar chain-recognizing receptor |
| 01/21/2010 | WO2010008083A1 Specimen test tube refrigeration and cold-storage system |
| 01/21/2010 | WO2010008075A1 Anti-system asc amino acid transporter 2 (asct2) antibody |
| 01/21/2010 | WO2010008051A1 Anti-human clcp1 antibody and use thereof |
| 01/21/2010 | WO2010008001A1 Aptamer against il-17 and use thereof |
| 01/21/2010 | WO2010007857A1 Method for stabilizing microparticles having reactive substance bound thereto, and reagent containing the microparticles |
| 01/21/2010 | WO2010007856A1 Blood property analysis system |
| 01/21/2010 | WO2010007734A1 Developing solution for immunochromatography, and measurement method using same |
| 01/21/2010 | WO2010007724A1 Peptide capable of binding to epcam |
| 01/21/2010 | WO2010007701A1 Therapeutic agent and test agent for disease with myocardial necrosis |
| 01/21/2010 | WO2010007613A1 Liquid–transfer device particularly useful as a capturing device in a biological assay process |
| 01/21/2010 | WO2010007580A1 Viscosimetric biosensor for monitoring analyte levels |
| 01/21/2010 | WO2010007531A2 Use of defensin alpha 1 and/or defensin alpha 4, as a marker for predicting treatment response and/or a relapse in a patient suffering from chronic myeloid leukaemia |
| 01/21/2010 | WO2010007528A2 Biomarkers for insulin efficacy |
| 01/21/2010 | WO2010007526A1 Biomarkers for cardiodiabetes |
| 01/21/2010 | WO2010007464A1 USE OF DEFENSIN α1 AND/OR DEFENSIN α4, AS A MARKER FOR PREDICTING A RELAPSE IN A PATIENT SUFFERING FROM CHRONIC MYELOID LEUKAEMIA |
| 01/21/2010 | WO2010007463A1 Human cytomegalovirus neutralising antibodies and use thereof |
| 01/21/2010 | WO2010007451A1 Nanosensor for determining the concentrations of physiologically active inorganic ions on subcellular level |
| 01/21/2010 | WO2010007443A2 Methods of determining properties of latent fingerprints |
| 01/21/2010 | WO2010007391A2 Hexacyanoferrate modified electrode |
| 01/21/2010 | WO2010007390A2 Method to assess multiphase fluid compositions |
| 01/21/2010 | WO2010007365A1 Immunotherapeutic method |
| 01/21/2010 | WO2010007329A2 Novel method for measuring insulin resistance |
| 01/21/2010 | WO2010007233A1 Method and device for detecting fluorescence from a biochip |
| 01/21/2010 | WO2010007214A1 Enzymatical modif ication of cell glycosylation using serum albumin and divalent cations |
| 01/21/2010 | WO2010007213A1 A method of evaluating the integrity of the plasma membrane of cells by detecting glycans found only intracellularly |
| 01/21/2010 | WO2010007175A2 Pacap signaling pathway modulators for treating inflammatory skin diseases with a neurogenic component, and more particularly rosacea and composition containing them |
| 01/21/2010 | WO2010007164A1 Method of assaying an aminoadamantane derivative |
| 01/21/2010 | WO2010007140A1 Method for in vitro assay of the circulating tissue factor, and use in the detection of coagulation diseases |
| 01/21/2010 | WO2010007132A1 Methods and kit for analyte detection |
| 01/21/2010 | WO2010007117A1 Method and device for producing organic compounds containing metal |
| 01/21/2010 | WO2010007106A1 Means and methods diagnosing gastric bypass and conditions related thereto |
| 01/21/2010 | WO2010007041A1 Multimarker panel for diagnosing, monitoring and selecting the therapy for patients with heart failure |
| 01/21/2010 | WO2010007000A1 Cancerous disease modifying antibodies |
| 01/21/2010 | WO2010006895A1 Operating method for a processing device processing a metal strip and system for processing a metal strip |
| 01/21/2010 | WO2010006703A1 G-protein coupled receptor 30 (gpr30) knockout mice as a model for cardiovascular diseases |
| 01/21/2010 | WO2010006616A2 Method and kit for examination of cells using n-(9-acridinyl)maleimide (nam) or using 7-diethylamino-3-((4'-(iodoacetyl)amino)phenyl)-4-methylcoumarin (cpi) |
| 01/21/2010 | WO2010006615A2 Method and kit for assessing viable cells |
| 01/21/2010 | WO2010006605A2 Thrombin substrate and assay for determining the level of bioactive thrombin in a sample |
| 01/21/2010 | WO2010006604A1 High capacity solid phase |
| 01/21/2010 | WO2010006603A1 Apparatus for hemolyzing a blood sample and for measuring at least one parameter thereof |
| 01/21/2010 | WO2010006601A1 Pax 5 monoclonal antibody |
| 01/21/2010 | WO2010006588A2 Method and device for analysing biogas |
| 01/21/2010 | WO2009146036A3 Quantification of differences between measured values and statistical validation based on the differences |
| 01/21/2010 | WO2009145478A3 Kit for the diagnosis of glaucoma |
| 01/21/2010 | WO2009145429A3 Proteins with pteridine glycosyltransferase activity and analysis method using the same |
| 01/21/2010 | WO2009143168A3 Vaccine assays |
| 01/21/2010 | WO2009142724A3 Novel gpr101 transgenic mice and methods of use thereof |
| 01/21/2010 | WO2009141352A3 Risk analysis in patients with and without metabolic syndrome |
| 01/21/2010 | WO2009140375A3 Phage-mediated bioluminescent detection of yersinia pestis |
| 01/21/2010 | WO2009138364A3 Means and methods for predicting renal failure in diabetes patients based on placental growth factor and soluble flt1 |
| 01/21/2010 | WO2009137605A3 AFFINITY MATURED CRIg VARIANTS |
| 01/21/2010 | WO2009137456A8 Systems, methods and devices for use in assessing carcass grading |
| 01/21/2010 | WO2009137241A3 Process for fabricating nanowire arrays |
| 01/21/2010 | WO2009132273A3 Microrna biomarkers of tissue injury |
| 01/21/2010 | WO2009131365A3 Cst1, dcc1, ifitm1 or melk as markers for diagnosing stomach cancer |
| 01/21/2010 | WO2009130612A3 Prion epitopes and methods of use thereof |
| 01/21/2010 | WO2009129220A3 Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma |
| 01/21/2010 | WO2009126609A3 A method for petrophysical evaluation of shale gas reservoirs |
| 01/21/2010 | WO2009126343A3 Oil emulsions and methods for manufacture and use thereof |
| 01/21/2010 | WO2009117680A3 Method for diagnosing and treating emphysema |
| 01/21/2010 | WO2009114945A9 Methods and kits for the differential diagnosis of alzheimer's disease versus frontotemporal dementia, and for the diagnosis of frontotemporal dementia, comprising fas-l and ckl 18 as biomarkers |
| 01/21/2010 | WO2009103741A3 Use of fsh receptor ligands for diagnosis and therapy of cancer |
| 01/21/2010 | WO2009103319A3 Ezrin, serpin b5, peroxiredoxin-2 and heat shock protein beta-1 as autoantigens for treating or detecting streptococcal diseases |
| 01/21/2010 | WO2009102493A3 Use of egfrviii to identify and target cancer stem cells |
| 01/21/2010 | WO2009100040A3 Cell lines expressing gaba receptor and methods using them |
| 01/21/2010 | WO2009094610A9 Novel cell lines expressing enac and methods using them |
| 01/21/2010 | WO2009094194A3 Diagnostic and therapeutic uses of gelsolin in renal failure |
| 01/21/2010 | WO2006039470A9 Anti- amyloid antibodies, compositions, methods and uses |
| 01/21/2010 | WO2004058153A9 Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476. |
| 01/21/2010 | WO2004041170A9 Compositions and methods for the treatment of immune related diseases |
| 01/21/2010 | WO2004024097A9 Compositions and methods for the treatment of immune related diseases |
| 01/21/2010 | WO2003070899A9 Phospho-specific antibodies to flt3 and uses thereof |
| 01/21/2010 | WO2003061561A9 Epsilon immunoglobulin chain derived peptides for induction of anti-ige antibodies |
| 01/21/2010 | WO2002078642A9 Differentially-expressed and up-regulated polynucleotides and polypeptides in breast cancer |
| 01/21/2010 | US20100017909 Nitrate transport components |
| 01/21/2010 | US20100017898 Therapeutic applications of noncovalent dimerizing antibodies |
| 01/21/2010 | US20100017897 Prrg4-associated compositions and methods of use thereof in methods of tumor diagnosis |
| 01/21/2010 | US20100017896 Filaggrin |
| 01/21/2010 | US20100017894 Mutants of Human App and Their Use for the Production of Transgenice Animals |
| 01/21/2010 | US20100017147 Amino-acid biosensor, Fischer-ratio biosensor and health information management system |
| 01/21/2010 | US20100017146 Auto-analysis framework for sequence evaluation |
| 01/21/2010 | US20100017145 Method of evaluating cancer state, cancer-evaluating apparatus, cancer-evaluating method, cancer-evaluating system, cancer-evaluating program and recording medium |
| 01/21/2010 | US20100017143 Gestational age dependent proteomic changes of human maternal serum for monitoring maternal and fetal health |
| 01/21/2010 | US20100017142 Low Perfusion Signal Processing Systems And Methods |
| 01/21/2010 | US20100017130 Method of ranking geomarkers and compositional allocation of wellbore effluents |
| 01/21/2010 | US20100016687 Signal processing for continuous analyte sensor |
| 01/21/2010 | US20100016562 Reducing the immunogenicity of fusion proteins |
| 01/21/2010 | US20100016557 HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha |
| 01/21/2010 | US20100016424 Production and use of derivatized homoserine lactones |
| 01/21/2010 | US20100016415 Proteins Expressed by Mycobacterium Tuberculosis and not by BCG and their use as Diagnostic Reagents and Vaccines |
| 01/21/2010 | US20100016411 Method of modulation of expression of epidermal growth factor receptor(egfr) involving mirna |
| 01/21/2010 | US20100016408 Modulating the cdc14b-cdh1-plk1 axis and methods for sensitizing target cells to apoptosis |
| 01/21/2010 | US20100016364 Method of predictive determination of responsiveness to pharmacological intervention |